Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91–7.

Article  CAS  PubMed  Google Scholar 

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.

Article  CAS  PubMed  Google Scholar 

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32:2712–7.

Article  CAS  PubMed  Google Scholar 

Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337–45.

Article  PubMed  PubMed Central  Google Scholar 

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. international myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904–12.

Article  CAS  PubMed  Google Scholar 

Ozkan HA, Bal C, Gulbas Z. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide. Transfus Apher Sci. 2014;50:46–52.

Article  PubMed  Google Scholar 

Shimura Y, Kuroda J, Uchiyama H, Kawata-Iida E, Tsutsumi Y, Nagoshi H, et al. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma. J Clin Apher. 2013;28:368–73.

Article  PubMed  Google Scholar 

Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, et al. A phase I study of the safety and feasibility of bortezomib in combination with G-CSF for stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19:e588–93.

Article  PubMed  PubMed Central  Google Scholar 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

Article  PubMed  Google Scholar 

Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

Article  CAS  PubMed  Google Scholar 

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

Article  CAS  PubMed  Google Scholar 

O’Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182:222–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okazuka K, Ishida T, Nashimoto J, Uto Y, Sato K, Miyazaki K, et al. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Eur J Haematol. 2020;104:110–5.

Article  CAS  PubMed  Google Scholar 

Suzuki K, Tsukada N, Nishimura N, Nagata Y, Okazuka K, Mishima Y, et al. Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis. Int J Hematol. 2020;111:103–11.

Article  CAS  PubMed  Google Scholar 

Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988–99.

Article  PubMed  PubMed Central  Google Scholar 

Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K, et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplant. 2009;43:793–800.

Article  CAS  PubMed  Google Scholar 

Ghobadi A, Rettig MP, Cooper ML, Holt MS, Ritchey JK, Eissenberg L, et al. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. Blood. 2014;124:2752–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keklik M, Karakus E, Kaynar L, Akyol G, Guven ZT, Celik S, et al. Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma. Transfus Apher Sci. 2020;59: 102844.

Article  PubMed  Google Scholar 

Roussel M, Hebraud B, Hulin C, Perrot A, Caillot D, Stoppa AM, et al. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020;61:1323–33.

Article  CAS  PubMed  Google Scholar